Authors’ commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy

Authors’ commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy

2017. Vol. 13, issue1

Bibliographic Details
Main Author: M. Y. Frolov
Format: Article
Language:Russian
Published: ABV-press 2017-06-01
Series:Onkourologiâ
Online Access:https://oncourology.abvpress.ru/oncur/article/view/691
Description
Summary:2017. Vol. 13, issue1
ISSN:1726-9776
1996-1812

Similar Items